Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PPL freezes AAT program, restructures

PPL Therapeutics (LSE:PTH) and partner Bayer (FSE:BAYG; BAY) put their recombinant alpha-1 antitrypsin (recAAT) development program on hold

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE